Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
CTD_human |
Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line.
|
8631603 |
1996 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that CYP2E1 and NQO1 genotypes may play an important role in development of smoking related bladder cancer among Korean men.
|
12777965 |
2003 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The variant allele genotypes of NQO1 were associated with a higher risk of bladder cancer in Caucasians (odds ratio (OR)=1.51; 95% confidence interval (CI)=1.01-2.25).
|
12694753 |
2003 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of glutathione S-transferase (GST) enzymes (M1, T1), methylenetetrahydrofolate (MTHFR) 677 and 1298, and the NAD(P)H:quinone oxidoreductase (NQO1) polymorphisms in a population-based bladder cancer case-control study in Argentina.
|
15219943 |
2004 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk.
|
14729580 |
2004 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue from 148 patients with low to intermediate grade (G1/G2) superficial (Ta/T1) bladder cancers and NQO1*2 genotype status determined by PCR-RFLP.
|
15375541 |
2004 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in NAD[P]H:quinone oxidoreductase (NQO1) and glutathione S-transferases (GSTs) have been reported to be associated with an increased risk for environmentally and/or occupationally induced renal and bladder cancers.
|
15365958 |
2004 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most notable findings are: GSTM1 deletion and bladder cancer risk [odds ratio (OR) = 1.60; 95% confidence interval 1.00-2.56]; CYP1A1 and leukemia (2.22, 1.33-3.70; heterozygotes); CYP1B1 and leukemia (0.47, 0.27-0.84; homozygotes); MnSOD and leukemia (1.91, 1.08-3.38; homozygotes) and NQO1 and lung cancer (8.03, 1.73-37.3; homozygotes).
|
17496311 |
2007 |
Malignant neoplasm of urinary bladder
|
0.600 |
Therapeutic
|
disease |
RGD |
Compared to the control group, a more preventive effect of SPUE and PPS treatment on bladder cancer was discovered, higher mRNA upregulation of GSTpi and NQO1 was seen in the treatment group.
|
21213404 |
2011 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Results of this study strongly suggest that the variant allele of NQO1 (Pro187Ser) may affect individual susceptibility to bladder cancer, particularly among smokers, in this ethnic Kashmiri population.
|
21253823 |
2011 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that NQO1 rs1800566 genetic polymorphism may contribute to bladder cancer development, especially in Asians.
|
23464456 |
2012 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the NQO1 rs1800566 polymorphism is not associated with a risk of bladder cancer.
|
23873104 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, our meta-analysis suggests that NQO1 C609T polymorphism is associated with bladder cancer susceptibility.
|
23749485 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, a meta-analysis of the Exon 6 (C > T) polymorphism and BC risk showed that the variant of NQO1 Exon 6 genotypes was associated with an overall increased risk of BC, which was consistent with the results of the present study.
|
24676794 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The highest odds for having bladder cancer following SH infection were observed among individuals with the CC genotypes for both NQO1 and SOD2 (OR [CI 95%] = 4.41 [2.32-8.38]).
|
24035474 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Compared with study participants carrying the C/C genotype of NQO1 gene, those with C/T and T/T genotypes had a significantly increased BC risk of 1.8 (95% CI = 1.1-2.9).
|
24315573 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Overall, the NQO1 187Ser carriers were associated with an increased bladder cancer risk (homozygous: OR = 1.43, 95% CI = 1.08-1.90; recessive: OR = 1.33, 95% CI = 1.03-1.72; dominant: OR = 1.19, 95% CI = 1.04-1.37, and allele comparing: OR = 1.18, 95% CI = 1.06-1.33).
|
25602258 |
2015 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
quinone oxidoreductase I (NQO1) and superoxide dismutase 2 (SOD2), and urinary bladder cancer risk among male agricultural workers in Egypt.
|
24219772 |
2015 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings have suggested that the NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism combination with smoking significantly confer susceptibility to BC.
|
28589969 |
2017 |